0001209191-20-036589.txt : 20200615
0001209191-20-036589.hdr.sgml : 20200615
20200615161736
ACCESSION NUMBER: 0001209191-20-036589
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200611
FILED AS OF DATE: 20200615
DATE AS OF CHANGE: 20200615
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bolzon Bradley J PhD
CENTRAL INDEX KEY: 0001354345
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37923
FILM NUMBER: 20963491
MAIL ADDRESS:
STREET 1: ONE SANSOME STREET
STREET 2: SUITE 3630
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CRISPR Therapeutics AG
CENTRAL INDEX KEY: 0001674416
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 473173478
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
BUSINESS PHONE: 6173154600
MAIL ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-06-11
0
0001674416
CRISPR Therapeutics AG
CRSP
0001354345
Bolzon Bradley J PhD
C/O CRISPR THERAPEUTICS, INC.
610 MAIN STREET
CAMBRIDGE
MA
02139
1
0
0
0
Stock Option (Right to Buy)
59.70
2020-06-11
4
A
0
15000
0.00
A
2030-06-11
Common Shares
15000
15000
I
See footnote
This option was granted on June 11, 2020 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2020; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2021 Annual General Meeting of Shareholders.
The Reporting Person is a managing member of Versant Venture Management, LLC and pursuant to agreement with Versant Venture Management, LLC, the Reporting Person is deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in Versant Venture Management, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
/s/ Michael Esposito, attorney-in-fact
2020-06-15